Target intelligence / Profile preview

Picornavirus capsid protein VP1 (VP1) (VP1)

Target
VP1
Molecular classification
Viral structural protein, Capsid protein
01

Overview

Picornavirus capsid protein VP1 is the primary surface-exposed structural protein of the Picornaviridae family, which includes pathogens such as Rhinovirus, Poliovirus, and Enterovirus 71 (UniProt: P03300). It plays a pivotal role in the viral life cycle by mediating attachment to host cell receptors, such as ICAM-1 or CD155, and facilitating the delivery of the viral RNA genome into the cytoplasm (PubMed: 11907214). A defining feature of VP1 in many picornaviruses is a hydrophobic "canyon" or pocket that is essential for receptor binding and serves as a major target for antiviral drug development (PubMed: 10482571). Small-molecule inhibitors, known as capsid binders, occupy this pocket to stabilize the virion and prevent the uncoating process necessary for infection (PubChem: CID 104314). These drugs, such as Pleconaril, effectively lock the viral capsid in a rigid state, thereby blocking the release of the viral genome (PubMed: 11907214). Due to its high degree of sequence variability, VP1 is also the standard target for molecular typing and phylogenetic analysis of picornavirus strains (PubMed: 12692194). Furthermore, mutations within the VP1 pocket are the primary mechanism by which viruses develop resistance to these antiviral agents (PubMed: 11907214).

Other names
Viral protein 11D proteinCapsid protein 1DVP1 structural protein
02

Mechanism of action

Capsid binders occupy a hydrophobic pocket within the VP1 protein, which stabilizes the viral capsid and prevents the conformational changes required for the release of viral RNA into the host cell (uncoating) (PubMed: 11907214). They may also interfere with viral attachment to host receptors by altering the "canyon" conformation (PubMed: 10482571).

03

Biological functions

Viral attachmentHost cell receptor bindingViral uncoatingGenome protectionViral assembly
04

Disease associations

InfectionCommon coldPoliomyelitisHand, foot, and mouth diseaseMyocarditisAseptic meningitis
05

Safety considerations

Rapid emergence of drug resistance mutations in the VP1 hydrophobic pocket (PubMed: 11907214)Narrow antiviral spectrum across different picornavirus serotypesPoor bioavailability and rapid metabolic clearance of early generation inhibitors (PubMed: 10482571)
06

Interacting drugs

Pleconaril

5 more in the full profile.

07

Biomarkers

Viral RNA loadVP1-specific neutralizing antibodiesVP1 sequence-based genotype for strain identification (PubMed: 12692194)

Beyond the preview

Go deeper on Picornavirus capsid protein VP1 (VP1) (VP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Picornavirus capsid protein VP1 (VP1) (VP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call